Center-Authored Papers

Filters: Author is Crowley, John  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Ludwig H, Bolejack V, Crowley J, Bladé J, Miguel JS, Kyle RA, Rajkumar VS, Shimizu K, Turesson I, Westin J et al..  2010.  Survival and years of life lost in different age cohorts of patients with multiple myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(9):1599-605. Abstract
Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B.  2010.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).. Blood. 116(26):5838-41. Abstract
Waldenstrom Macroglobulinemia
Dhodapkar MV, Hoering A, Gertz MA, Rivkin S, Szymonifka J, Crowley J, Barlogie B.  2009.  Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.. Blood. 113(4):793-6. Abstract
Usmani S, Sexton R, Crowley J, Barlogie B.  2011.  Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.. Clinical lymphoma, myeloma & leukemia. 11(1):139-42. Abstract
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP et al..  2009.  International prognostic scoring system for Waldenstrom macroglobulinemia.. Blood. 113(18):4163-70. Abstract
Vitamin E
Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano MJ, Hartline JA et al..  2009.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 301(1):39-51. Abstract
Klein EA, Thompson IM, Tangen CM, Crowley J, Lucia SM, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano MJ et al..  2011.  Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 306(14):1549-56. Abstract
Validation Studies as Topic
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP et al..  2009.  International prognostic scoring system for Waldenstrom macroglobulinemia.. Blood. 113(18):4163-70. Abstract
Urea
Greenberg RE, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, Dominguez RL, Ferreccio C, Herrero R, Lazcano-Ponce EC et al..  2011.  14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.. Lancet. 378(9790):507-14. Abstract
Up-Regulation
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E et al..  2011.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3.. Blood. 118(13):3512-3524. Abstract
United States
Albain KS, Unger JM, Crowley J, Coltman CA, Hershman DL.  2009.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.. Journal of the National Cancer Institute. 101(14):984-92. Abstract
Gandara DR, Kawaguchi T, Crowley J, Moon J, Furuse K, Kawahara M, Teramukai S, Ohe Y, Kubota K, Williamson SK et al..  2009.  Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(21):3540-6. Abstract
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
Tumor Suppressor Protein p53
Shaughnessy JD, Zhou Y, Haessler J, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Epstein J, Crowley J et al..  2009.  TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.. British journal of haematology. 147(3):347-51. Abstract
Tumor Markers, Biological
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Shaughnessy JD, Hoering A, Crowley J et al..  2010.  Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.. Blood. 116(8):1220-7. Abstract
Hoering A, LeBlanc M, Crowley J.  2008.  Randomized phase III clinical trial designs for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14):4358-67. Abstract
Durie BGM, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA et al..  2009.  Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(10):1913-9. Abstract
Herbst RS, Kelly K, Chansky K, Mack PC, Franklin WA, Hirsch FR, Atkins JN, Dakhil SR, Albain KS, Kim ES et al..  2010.  Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(31):4747-54. Abstract
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E et al..  2011.  Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with total therapy 3.. Blood. 118(13):3512-3524. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
Triazines
Le Q-TX, Moon J, Redman MW, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley J, Moore DF, Gandara DR.  2009.  Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(18):3014-9. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract
Treatment Outcome
Davies AM, Chansky K, Lara PN, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR.  2009.  Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 4(1):87-92. Abstract
Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le Q-T, Crowley J, Gandara DR.  2008.  Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(29):4771-6. Abstract